ArticleMediterranean journal of rheumatology2026
Patients' Journey and Burden of Disease Among Patients with Axial Spondyloarthritis in Greece: A Cross-Sectional Online Survey.
Article in Mediterranean journal of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective/Aim: This study investigates the patient journey and humanistic and economic burden of axial spondyloarthritis (axSpA) in Greece, addressing a gap in real-world data on patient experiences. Methods: A cross-sectional online survey was conducted between September 2023 - February 2024, among axSpA patients 18 years old and above, members of the Greek patients' association "Reumazin". Data collection included socio-demographic characteristics, medical history, quality of life via Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire, work productivity impairment, treatments and resource use, and patients' expenditures over the past 12 months. Economic burden was assessed as out-of-pocket expenses and indirect cost. Results: 150 patients participated (47% female; median age 57 years). The median time from symptom onset to diagnosis and to treatment initiation was 14.8 and 19 months, respectively. The most common initial symptoms were back pain (77%) and stiffness (51%). Initial specialists visited included orthopedics (53%) and pathologists/general practitioners (30%), with 63% initially misdiagnosed. The median ASQoL score was 8 (Q1: 5, Q3: 12). Among employed participants (40%), median work time impaired was 30% and activity time impaired was 40%. Mean annual out-of-pocket expenses were €400 (95% CI: €354 - €453), primarily driven by treatment costs (69%). Indirect costs were €3,321 (95% CI: €2,552 - 4,447) with presenteeism cost accounting for 84%. Conclusion: This study highlights diagnostic delays and the humanistic and economic burdens of patients living with axSpA in Greece, filling a critical gap in the literature and supporting healthcare providers and policymakers in improving patient care and optimising resource allocation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.